Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

References

• Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338: 853–60
   Google Scholar
• Fätkenheuer G, Theisen A, Rockstroh J, Grabow T, Wicke C, Becker K, Wieland U, Pfister H, Reiser M, Hegener P, Franzen C, Schwenk A, Salzberger B. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV- infected patients. AIDS 1997;11:F113–F116
   Google Scholar
• Wit FWNM, van Leeuwen R, Weverling GJ, Jurriaans S, Nauta K, Steingrover R, Schuijtemaker J, Eyssen X, Fortuin D, Weeda M, de Wolf F, Reiss P, Danner SA, Lange JM. Outcome and predictors of failure of highly active antiretroviral therapy: one- year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999;179:790–8
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292:191–201
   PubMed Web of Science ®Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh SWR. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19:685–94
   Google Scholar
• Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 2000;19:124–33
   Google Scholar
• Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr 2002;29(Suppl 1):S2–S10
   PubMedGoogle Scholar
• Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000;30(Suppl 2):S171–S176
   PubMed Web of Science ®Google Scholar
• Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21–30
   PubMed Web of Science ®Google Scholar
• Svedhem V, Lindkvist A, Lidman K, Sönnerborg A. Persistence of earlier HIV-1 drug resistance mutations at new treatment failure. J Med Virol 2002;68: 473–8
   Google Scholar
• Kantor R, Fessel WJ, Zolopa AR, Israelski D, Shulman N, Montoya JG, Harbour M, Schapiro JM, Shafer RW. Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. Antimicrob Agents Chemother 2002;46: 1086–92
   Google Scholar
• Miller V. International perspectives on antiretroviral resistance. Resistance to protease inhibitors. J Acquir Immune Defic Syndr 2001;26(Suppl 1):S34–S50
   PubMedGoogle Scholar
• Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [updated March 23, 2004]. Available from http://aidsinfo.nih.gov/guidelines/adult/AA_032304.pdf [Accessed 17 September 2004]
   Google Scholar
• Feinberg J, Brun S, Xu Y, Marsh T, Benson C, Deeks S, Kessler H, Murphy R, Gulick R, Wheeler D, Hicks C, Eron J, Sax P, Stryker R, Riddler S, et al, for the M97–765 Study Group. Durable suppression of HIV+ RNA after 2 years of therapy with ABT-378/ritonavir (ABT-378/r) treatment in single protease inhibitor experienced patients [abstract P101 ]. AIDS 2000;14\(Suppl 4):S46
   Google Scholar
• Clumeck N, Brun S, Sylte J, Isaacson J, Chen S, Lazzarin A, Girard PM, Rockstroh J, Becker S, Telenti A, Bergmann F, Danner S, Ho D, Tubiana R, Carosi G, et al. Kaletra (ABT-378/r) and efavirenz: one-year safety/efficacy evaluation and phenotypic breakpoints in multiple-PI-experienced patients [abstract 525]. Available from http://retroconference.org/2001/abstracts/%20abstracts/abstracts/525.htm [Accessed 27 September 2001]
   Google Scholar
• Katlama C, Schneider L, Agher R, Delaugerre C, Calvez V, Legrand M, Tubiana R. Ritonavir (RTV) /amprenavir (APV) combination therapy in HIV infected patients who failed several protease inhibitor containing regimen [abstract 673]. Available from http://www.ias.se/print.asp?abstract%20id=673 [Accessed 15 August 2001]
   Google Scholar
• De Mendoza C, Martín-Carbonero L, Barreiro P, Diaz B, Valencia E, Jiménez-Nácher I, Gallego O, Nuñez M, González-Lahoz J, Soriano V. Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. HIV Clin Trials 2002;3:304–9
   PubMedGoogle Scholar
• Katner HP, Paar DP, Nadler JP, Jensen EH, Wilson HM, Finn TS, Petruschke RA, Zeldin RK. Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen. J Acquir Immune Defic Syndr 2002;31:483–7
   PubMed Web of Science ®Google Scholar
• Arvieux C, Tattevin P, Souala FM, Jaccard P, Ruffault A, Bentué-Ferrer D, Tribut O, Chapplain JM, Dupont M, Bouvier C, Michelet C. Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients. HIV Clin Trials 2002;3: 125–32
   Google Scholar
• Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, Murphy RL, Hicks C, King M, Wheeler D, Feinberg J, Stryker R, Sax PE, Riddler S, Thompson M, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002;185:599–607
   PubMed Web of Science ®Google Scholar
• DeJesus E, LaMarca A, Sension M, Beltran C, Yeni P. The Context study: efficacy and safety of GW433908/RTV in PI- experienced subjects with virological failure (24 week results) [abstract 178]. Available from http://www.retroconference.%20org/2003/Abstract/Abstract.aspx?AbstractID%20=%20286 [Accessed 15 May 2003]
   Google Scholar
• O'Mara E, Mummaneni V, Randall D, Sagali N, Olsen S, Tanner T, Schuster AE, Raymond R, Kaul S. BMS-232632: a summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects [abstract 504]. Available from http://%20www.retroconference.org/2000/abstracts/504.htm [Accessed 4 February 2004]
   Google Scholar
• Sanne I, Piliero P, Squires K, Thiry A, Schnittman S for the AI424–007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424–007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003;32: 18–29
   Google Scholar
• Murphy RL, Sanne I, Cahn P, Phanupak P, Percival L, Kelleher T, Giordano M. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003;17: 2603–14
   Google Scholar
• Haas DW, Zala C, Schrader S, Piliero P, Jaeger H, Nunes D, Thiry A, Schnittman S, Sension M. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 2003;17:1339–49
   Google Scholar
• DeJesus E, Grinsztejn B, Rodriguez C, Nieto-Cisneros L, Coco J, Lazzarin A, Lichtenstein K, Johnson M, Rightmire A, Sankoh S, Wilber R. Efficacy and safety of atazanavir with ritonavir or saquinavir vs lopinavir/ritonavir in patients who have experienced virologic failure on multiple HAART regimens: 48-week results from BMS A1424–045 [abstract 547]. Available from http://%20www.retroconference.org/2004/cd/Abstract/547.htm [Accessed 10 May 2005]
   Google Scholar
• Clotet B, Lazzarin A, Grinsztejn B, Lichtenstein K, Sankoh S, Wilber R. Safety assessment of patients receiving atazanavir (ATV) with ritonavir (RTV), ATV with saquinavir (SQV), or lopinavir (LPV)/RTV: 48-week results from BMS A1424–045 [abstract PP 4.57]. Available from http://www.isheid.com/faq-%20286.htm [Accessed 14 June 2004]
   Google Scholar
• Colonno RJ, Thiry A, Limoli K, Parkin N. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother 2003;47: 1324–33
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51–F58
   Google Scholar
• Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, Lo JC, Schambelan M. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23:35–43
   PubMed Web of Science ®Google Scholar
• Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS 1997;11:938–9
   PubMed Web of Science ®Google Scholar
• Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V, Aguado AG, de Lomas JG, Delgado R, Borleffs JCC, Hsu A, et al for the European-Australian Collaborative Ritonavir Study Group.A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333: 1528–33
   Google Scholar
• Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Körner T, Stoll M, Schmidt RE. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63–F70
   Google Scholar
• Périard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R, Mooser V for the Swiss HIV Cohort Study. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999;100:700–5
   Google Scholar
• Rickerts V, Brodt HR, Staszewski S, Stille W. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 2000;5:329–33
   PubMedGoogle Scholar
• Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, D’Arminio MA, Pradier C, Morfeldt L, Mateu S, Law M, El Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD for the DAD Study Group. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179–93
   Google Scholar
• Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, Greenberg AE, Janssen RS and the HIV Outpatient Study (HOPS) Investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV-1 [letter]. Lancet 2002;360: 1747–8
   Google Scholar
• Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479–86
   Google Scholar